Summary
Global Markets Direct’s, ‘Diphtheria - Pipeline Review, H1 2016’, provides an overview of the Diphtheria pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Diphtheria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Diphtheria
- The report reviews pipeline therapeutics for Diphtheria by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diphtheria therapeutics and enlists all their major and minor projects
- The report assesses Diphtheria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diphtheria
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diphtheria
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diphtheria pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Beijing Minhai Biotechnology Co., Ltd
Biological E. Limited
Boryung Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
GlaxoSmithKline Plc
Green Cross Corporation
Indian Immunologicals Limited
LG Life Science LTD.
Panacea Biotec Limited
Prometheon Pharma, LLC
Sanofi Pasteur SA
Serum Institute of India Limited
Sinovac Biotech Ltd.
Zydus Cadila Healthcare Limited
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Diphtheria Overview 10
Therapeutics Development 11
Pipeline Products for Diphtheria - Overview 11
Pipeline Products for Diphtheria - Comparative Analysis 12
Diphtheria - Therapeutics under Development by Companies 13
Diphtheria - Therapeutics under Investigation by Universities/Institutes 15
Diphtheria - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Diphtheria - Products under Development by Companies 19
Diphtheria - Products under Investigation by Universities/Institutes 21
Diphtheria - Companies Involved in Therapeutics Development 22
Beijing Minhai Biotechnology Co., Ltd 22
Biological E. Limited 23
Boryung Pharmaceutical Co., Ltd. 24
Daiichi Sankyo Company, Limited 25
GlaxoSmithKline Plc 26
Green Cross Corporation 27
Indian Immunologicals Limited 28
LG Life Science LTD. 29
Panacea Biotec Limited 30
Prometheon Pharma, LLC 31
Sanofi Pasteur SA 32
Serum Institute of India Limited 33
Sinovac Biotech Ltd. 34
Zydus Cadila Healthcare Limited 35
Diphtheria - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole-cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole-cell) + tetanus) (pentavalent) vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
(diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
(diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
(diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
(diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
(diphtheria + tetanus) vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
diphtheria + pertussis(acellular) + tetanus vaccine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
diphtheria vaccine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Eupenta - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
GC-1107 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
GC-3111A - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
LBVD - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
VN-0103 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
VN-0105 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Diphtheria - Recent Pipeline Updates 77
Diphtheria - Dormant Projects 79
Diphtheria - Discontinued Products 80
Diphtheria - Product Development Milestones 81
Featured News & Press Releases 81
Mar 21, 2016: BE Receives an Order from Govt. of India to Supply Liquid Pentavalent Vaccines 81
Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta 81
Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program 82
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine 82
Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age 83
Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 83
Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 84
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 85
Jun 22, 2012: Sanofi Pasteur’s Hexaxim Receives Positive Opinion from European Medicines Agency 85
Mar 13, 2008: U.S. FDA Licenses DAPTACEL Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series 87
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 88
Disclaimer 89
List of Tables
Number of Products under Development for Diphtheria, H1 2016 11
Number of Products under Development for Diphtheria - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2016 21
Diphtheria - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 22
Diphtheria - Pipeline by Biological E. Limited, H1 2016 23
Diphtheria - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016 24
Diphtheria - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 25
Diphtheria - Pipeline by GlaxoSmithKline Plc, H1 2016 26
Diphtheria - Pipeline by Green Cross Corporation, H1 2016 27
Diphtheria - Pipeline by Indian Immunologicals Limited, H1 2016 28
Diphtheria - Pipeline by LG Life Science LTD., H1 2016 29
Diphtheria - Pipeline by Panacea Biotec Limited, H1 2016 30
Diphtheria - Pipeline by Prometheon Pharma, LLC, H1 2016 31
Diphtheria - Pipeline by Sanofi Pasteur SA, H1 2016 32
Diphtheria - Pipeline by Serum Institute of India Limited, H1 2016 33
Diphtheria - Pipeline by Sinovac Biotech Ltd., H1 2016 34
Diphtheria - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 35
Assessment by Monotherapy Products, H1 2016 36
Assessment by Combination Products, H1 2016 37
Number of Products by Stage and Target, H1 2016 39
Number of Products by Stage and Route of Administration, H1 2016 41
Number of Products by Stage and Molecule Type, H1 2016 43
Diphtheria Therapeutics - Recent Pipeline Updates, H1 2016 77
Diphtheria - Dormant Projects, H1 2016 79
Diphtheria - Discontinued Products, H1 2016 80
List of Figures
Number of Products under Development for Diphtheria, H1 2016 11
Number of Products under Development for Diphtheria - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Products, H1 2016 18
Assessment by Monotherapy Products, H1 2016 36
Assessment by Combination Products, H1 2016 37
Number of Products by Targets, H1 2016 38
Number of Products by Stage and Targets, H1 2016 38
Number of Products by Routes of Administration, H1 2016 40
Number of Products by Stage and Routes of Administration, H1 2016 40
Number of Products by Molecule Types, H1 2016 42
Number of Products by Stage and Molecule Types, H1 2016 42
